Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents

Transcription

1 Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents Jarrad M Scarlett 1,,1, Jennifer M Rojas 1,1, Miles E Matsen 1, Karl J Kaiyala 3, Darko Stefanovski, Richard N Bergman 5, Hong T Nguyen 1, Mauricio D Dorfman 1, Louise Lantier, David H Wasserman, Zaman Mirzadeh 7, Terry G Unterman,9, Gregory J Morton 1 & Michael W Schwartz 1 SUPPLEMENTARY FIGURE LEGENDS SUPPLEMENTARY FIGURE 1 Effect of i.c.v. on glucoregulatory hormones in diabetic mice. (a) Plasma levels of insulin (left) and glucagon (right) in h fasted ob/ob (B) mice 1 weeks after a single i.c.v. injection of either 3 µg of m (n = 9) or veh (n = ). (b) Time course of blood glucose levels (left), food intake (middle) and body weight (right) from adlib-fed ob/ob (B) mice following a single injection of m (3 µg; n = 1) or veh (n = ) into the 3 rd ventricle. Throughout, data are the mean ± s.e.m. (a) P = n.s., i.c.v. m versus veh as determined by two-tailed Student s t-test. (b) P <.1 for group (veh versus ) by repeated measures designs by linear mixed-model analyses. P <.5, icv m versus veh by mixed factorial analyses. SUPPLEMENTARY FIGURE Effect of i.c.v. on plasma corticosterone levels in diabetic mice. Plasma levels of corticosterone obtained h after injection of m (3 µg) or veh into either (a) the 3 rd ventricle (veh, n = ;, n = 1) or (b) the lateral ventricle (veh, n = 1;, n = 1) from ob/ob (B) mice. (c) Plasma levels of corticosterone levels in ob/ob (B) mice 1 weeks after a single i.c.v. injection of either m (3 µg; n = 9) or veh (n = ). In all Nature Medicine: doi:1.13/nm.11

2 instances, plasma was obtained during mid-light cycle following a h fast. Throughout, data are mean ± s.e.m. P = n.s., i.c.v. m versus veh as determined by two-tailed Student s t-test. SUPPLEMENTARY FIGURE 3 Effect of i.c.v. on food intake and body weight across multiple rodent models of TD. (a) Time course of food intake (left) and body weight (right) from ad-lib-fed db/db mice following i.c.v. injection of either 3 µg of m (n = ) or veh (n = 9). (b) Time course of food intake (left) and body weight (right) from ad-lib-fed DIO WT mice in which hyperglycemia was induced with low-dose STZ (DIO-LD STZ) following i.c.v. injection of either m (3 µg; n = ) or veh (n = ). (c) Time course of food intake (left) and body weight (right) from ad-lib-fed ob/ob (B) mice following a single i.c.v. injection of either h (3 µg; n=), m (3 µg; n = ) or veh (n = ). (d) Time course of food intake (left), body weight (middle), and fat mass (right) from ad-lib-fed ZDF rats following a single i.c.v. injection of either r (3 µg; n = 1) or veh (n = 1). Throughout, data are the mean ± s.e.m. (a c) P <.5, i.c.v. m versus veh; # P <.5, i.c.v. h versus veh by mixed factorial analyses. (d) Significant main effects in (left) (P <.1) and (middle) (P =.) reflected group differences at earlier time points (treatment by day interaction is significant (P <.1). P-values for group (veh versus ) by repeated measures designs by linear mixed-model analyses. SUPPLEMENTARY FIGURE Effect of i.c.v. on BAT Ucp1 gene expression and plasma lipid levels. (a) Brown adipose tissue (BAT) Ucp1 gene expression in ob/ob (B) mice that underwent a basal glucose turnover study followed by an FSIGT 7 d after a single i.c.v. Nature Medicine: doi:1.13/nm.11

3 injection of m (3 µg; n = 13) or veh (n = 9). (b) Plasma levels of triglycerides (left), cholesterol (middle) and non-esterified free fatty acids (NEFA; right) in h fasted ob/ob (B) mice from samples obtained d following a single i.c.v. injection of either h (3 µg; n = ), m (3µg; n = ) or veh (n = ). (c) Plasma levels of triglycerides (left), cholesterol (middle), and NEFA (right) in h fasted db/db mice from samples obtained d following a single i.c.v. injection of either m (3 µg; n = ) or veh (n = 9). Throughout, data are mean ± s.e.m. P <.5, i.c.v. h versus veh as determined by one-way ANOVA analyses. SUPPLEMENTARY FIGURE 5 Effect of severe hyperglycemia on central -mediated glucose lowering. (a) Time course of blood glucose levels from severely hyperglycemic, ad-libfed db/db mice following i.c.v. injection of m (n = ) or veh (n = 9). (b) Time course of blood glucose levels from severely hyperglycemic, ad-lib-fed DIO WT mice treated with high dose-stz (DIO-HD STZ) following i.c.v. injection of m (n = ) or veh (n = 3). (c) Time course of blood glucose levels from severely hyperglycemic, ad-lib-fed ob/ob (BTBR) mice following i.c.v. injection of m (n = ) or veh (n = ). (d) Food intake (left), body weight (middle) and blood glucose (right) levels from ad-lib-fed DIO WT mice receiving continuous s.c. infusion of the insulin receptor antagonist S91 that received i.c.v. injection of either veh (n = 1) or m (3 µg; n = 11). Throughout, data are mean ± s.e.m. (d) For the time course of food intake (left), the groups differed on days 1 and (P <.1 and P =.3, respectively). P-values for group (veh versus ) by repeated measures designs by linear mixed-model analyses. Nature Medicine: doi:1.13/nm.11

4 SUPPLEMENTARY FIGURE Effect of i.c.v. in LIRFKO and littermate IRF control mice made hyperglycemic by systemic administration of the insulin receptor antagonist S91. Food intake (left) body weight (middle) and blood glucose levels (right) from ad-lib-fed littermate IRF controls (a) and LIRFKO mice (b) in which hyperglycemia was induced by continuous s.c. infusion of the insulin receptor antagonist S91, following i.c.v. injection of either veh (IRF, n = 1; LIRFKO, n = 1) or m (3 µg; IRF, n = 13; LIRFKO, n = 11). Throughout, data are mean ± s.e.m. P<.5, i.c.v. m versus veh by mixed factorial analyses. SUPPLEMENTARY FIGURE 7 (a) Representative immunofluorescence images of c-fos (red) in the hypothalamus of mice euthanized 9 min after a single i.c.v. injection of either veh saline (left, of n = images), m (3 µg; middle, of n = 1 images) or h9 (3 µg; right, of n = 1 images) (original magnification, x; Scale bar: µm). (b) C-Fos immunoreactive nuclei quantified from cells (both ependymal and tanycytes) lining the 3 rd ventricle (3V) from anatomically matched sections from the hypothalamus of mice treated with either i.c.v. veh (n = ), m (n = ) or h9 (n = ). (c) Hypothalamic levels of Hspb1 mrna (encoding HSP5) obtained from chow-fed WT mice h after a single i.c.v. injection of either veh (n = 9) or m (3 µg; n = ). (d) Western blot image (left) and densitometry quantification of synaptophysin protein levels (right) in hypothalamus (normalized to the loading control, β- tubulin III) from ob/ob mice obtained 1 week following a single i.c.v. injection of either m (3 µg; n = ) or veh (n = 5). Throughout, data are mean ± s.e.m. P <.5, i.c.v. m versus veh as determined by one-way ANOVA analysis or by Student s two-tailed t-test. Nature Medicine: doi:1.13/nm.11

5 Supplementary Figure 1 a Insulin (ng/ml) Glucagon (pmol/liter) 1..5 b Nature Medicine: doi:1.13/nm.11

6 Supplementary Figure a b c Corticosterone (ng/ml) Corticosterone (ng/ml) Corticosterone (ng/ml) Nature Medicine: doi:1.13/nm.11

7 Supplementary Figure 3 a m b _ m _ 1 3 c d Food intake (g/rat/day) h m # # 7 9 Time (h) # r ####### h m Fat mass (g) r 3 Nature Medicine: doi:1.13/nm.11

8 Supplementary Figure a BAT Ucp1 mrna (fold change) 1 m b Triglycerides (mg/dl) h m Cholesterol (mg/dl) NEFA (mmol/liter) c Triglycerides (mg/dl) m Cholesterol (mg/dl) NEFA (mmol/liter) Nature Medicine: doi:1.13/nm.11

9 Supplementary Figure 5 a b c _ 1 _ d 3 1 _ 1 1 Osmotic pump Icv injection _ 1 1 Nature Medicine: doi:1.13/nm.11

10 Supplementary Figure a Osmotic pump Icv injection b Osmotic pump Icv injection Nature Medicine: doi:1.13/nm.11

11 Supplementary Figure 7 a b 3V lining c-fos count (immunoreactive nuclei/section) c Hypothalamic Hspb1 mrna (fold change ) 1 d Hypothalamic synaptophysin/ -tubulin III (a.u.) Nature Medicine: doi:1.13/nm.11